Key Drivers
- Gross margin strength
- Cash burn
- High leverage
AIAI Summary
QURE has shifted from a pure speculative biotech to a credible FDA-path story after accelerated approval became feasible for AMT-130, but after the sharp rerating investors should focus on whether the next data and disclosures stay clean because weak operating cash flow still leaves meaningful dilution risk if the timeline slips.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross margin strength
- •Cash burn
- •High leverage
QURE shows strong gross margins and liquidity, but persistent losses, heavy cash burn, rising leverage, dilution, and expensive valuation outweigh the positives.
Price Behavior
Key Price Behavior Insights:
- •Re-rating surge
- •Fading momentum
- •Support holding
Over the last month, QURE remains structurally constructive after a sharp June re-rating, but fading momentum means it must hold the low-$40s and reclaim the mid-to-high $40s to avoid turning the breakout into a failed rally.
Sharp jump from the high-$20s to the high-$40s on 2026-06-16 to 2026-06-17
Sentiment & News
Key News Insights:
- •FDA pathway
- •Capital raise
- •Early seizure data
uniQure rallied after the FDA allowed Phase I/II AMT-130 data to support accelerated approval, while a larger financing and encouraging early AMT-260 epilepsy results reinforced momentum and capital strength.
The news is materially positive for QURE, improving regulatory visibility and funding flexibility while keeping clinical momentum in focus
Similar Companies in Healthcare
Other companies in the same sector with AI ratings